About Us

Product formulation through pharmaceutical & engineering research

Avocet Polymer Technologies, Inc. is a well-established pharmaceutical company that is dedicated to providing safe and effective therapies for inflamed, painful, and hypertrophic scars. Avocet was founded in 1996 and has been producing leading products that are based on known pharmacology and drug delivery technology. Headquartered in Chicago, Illinois, the company designs, manufacturers, develops and markets drugs, ointments and devices for the treatment of scar conditions.

Avogel & Avosil

Avocet distinguishes itself from other scar product development companies through its rational design of scar treatment and prevention therapies. Avocet currently has two products on the market, Avogel and Avosil, which are widely used by patients around the world for control of healing burn and trauma scars during the first year after injury. Avocet is committed to bringing these effective and affordable products into a greater number of hospitals, pharmacies, and homes across the country.

Patents

Avocet has more than 30 patents and has several new scar prevention and reduction products under development. Avocet's technology helps prevent scarring of the skin and of internal organs.

Avogel-SA Hydrogel Sheeting

Avocet has incorporated the powerful anti-inflammatory and preservative agent salicylic acid in a new hydrogel composition. The new proprietary hydrogel formulation is FDA approved. It is the most adhesive hydrogel on the market and it retains water better than any other hydrogel we have tested. It is thinner, more flexible and more adhesive than the previous hydrogel we have marketed as Avogel. It also contains salicylic acid. This concept is covered in patents filed by Avocet. Avogel-SA® should be more effective than any existing product in controlling scar itching and scar formation, especially when applied in the first year following wound generation. Avogel-SA® should lead to significantly improved functional and cosmetic results for post-surgical patients and survivors of major burns or trauma.

Avosil - V

The second product line that Avocet plans to develop targets older, mature scars. Avocet will develop hydrogels and ointments containing calcium channel blockers to activate scar degradation enzymes, which soften and reduce the size of the scar. This therapeutic approach is also covered by Avocet’s patents. An application for an international patent under the Paris Convention Treaty has been filed.

Avosil - D

Vitamin D3 inhibits NF-kB activation of cell inflammatory responses. Avocet has recently developed a novel formulation of Vitamin D3 to soften and diminish the appearance of older scars. An application for an international patent under the Paris Convention Treaty has been filed